ES2134588T3 - Uso de compuestos de carbazol para la preparacion de un medicamento para el tratamiento de la insuficiencia cardiaca congestiva. - Google Patents

Uso de compuestos de carbazol para la preparacion de un medicamento para el tratamiento de la insuficiencia cardiaca congestiva.

Info

Publication number
ES2134588T3
ES2134588T3 ES96902984T ES96902984T ES2134588T3 ES 2134588 T3 ES2134588 T3 ES 2134588T3 ES 96902984 T ES96902984 T ES 96902984T ES 96902984 T ES96902984 T ES 96902984T ES 2134588 T3 ES2134588 T3 ES 2134588T3
Authority
ES
Spain
Prior art keywords
sub
molecular weight
low molecular
hydrogen
carbon atoms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96902984T
Other languages
English (en)
Inventor
Mary Ann Lukas-Laskey
Robert Ruffolo Jr
Neil Shusterman
Gisbert Sponer
Klaus Strein
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BOEHRINGER MANNHEIM PHARMACEUTICALS CORPORATION-SMITHKLINE BEECHAM CORPORAT LTED PARTNERSHIP NO 1
Roche Diagnostics Corp
Original Assignee
BOEHRINGER MANNHEIM PHARMACEUTICALS CORPORATION-SMITHKLINE BEECHAM CORPORAT LTED PARTNERSHIP NO 1
Boehringer Mannheim Pharmaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26012210&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2134588(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from DE1995103995 external-priority patent/DE19503995C2/de
Application filed by BOEHRINGER MANNHEIM PHARMACEUTICALS CORPORATION-SMITHKLINE BEECHAM CORPORAT LTED PARTNERSHIP NO 1, Boehringer Mannheim Pharmaceuticals Corp filed Critical BOEHRINGER MANNHEIM PHARMACEUTICALS CORPORATION-SMITHKLINE BEECHAM CORPORAT LTED PARTNERSHIP NO 1
Application granted granted Critical
Publication of ES2134588T3 publication Critical patent/ES2134588T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrrole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

UN METODO DE TRATAMIENTO QUE UTILIZA UN COMPUESTO DE FORMULA (I), DONDE R{SUB,1} ES HIDROGENO, ALCANOILO DE BAJO PESO MOLECULAR DE HASTA 6 ATOMOS DE CARBONO O AROILO SELECCIONADO ENTRE BENZOILO Y NAFTOILO; R{SUB,2} ES HIDROGENO, ALQUILO DE BAJO PESO MOLECULAR DE HASTA 6 ATOMOS DE CARBONO O ARILALQUILO SELECCIONADO ENTRE BENCILO, FENILETILO Y FENILPROPILO, R{SUB,3} ES HIDROGENO O ALQUILO DE BAJO PESO MOLECULAR DE HASTA 6 ATOMOS DE CARBONO; R{SUB,4} ES HIDROGENO O ALQUILO DE BAJO PESO MOLECULAR DE HASTA 6 ATOMOS DE CARBONO, O CUANDO X ES OXIGENO, R{SUB,4} JUNTO CON R{SUB,5} PUEDEN REPRESENTAR ES UN ENLACE DE VALENCIA, SELECCIONA A PARTIR DE FENILO, NAFTILO, INDANILO Y TETRAHIDRONAFTILO; R{SUB,5} Y R{SUB,6} SE SELECCIONAN INDIVIDUALMENTE A PARTIR DE HIDROGENO, FLUOR, CLORO, BROMO, HIDROXILO, ALQUILO DE BAJO PESO MOLECULAR DE HASTA 6 ATOMO DE CARBONO, UN GRUPO NH{SUB,2} -, ALCOXI DE BAJO PESO MOLECULAR DE HASTA 6 ATOMOS DE CARBONO, BENCILOXI, ALQUILTIO DE BAJO PESO MOLECULAR DE HASTA 6 ATOMOS DE CARBONO, ALQUILSULFONILO DE BAJO PESO MOLECULAR DE HASTA 6 ATOMOS DE CARBONO; O R{SUB,5} Y R{SUB,6} REPRESENTAN CONJUNTAMENTE METILENDIOXI; O UNA SAL FARMACEUTICAMENTE ACEPTABLE DE LOS MISMOS, PREFERIBLEMENTE CARVEDILOL, SOLO O EN COMBINACION CON UNO O MAS AGENTES TERAPEUTICOS DISTINTOS, SIENDO DICHOS AGENTES SELECCIONADOS DE UN GRUPO CONSTITUIDO POR INHIBIDORES DE ECA, DIURETICOS Y GLUCOSIDOS CARDIOTONICOS PARA REDUCIR LA MORTALIDAD ASOCIADA A LA INSUFICIENCIA CARDIACA CONGESTIVA (CHF) EN MAMIFEROS, ESPECIALMENTE EN HUMANOS.
ES96902984T 1995-02-08 1996-02-07 Uso de compuestos de carbazol para la preparacion de un medicamento para el tratamiento de la insuficiencia cardiaca congestiva. Expired - Lifetime ES2134588T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE1995103995 DE19503995C2 (de) 1995-02-08 1995-02-08 Verwendung von Carvedilol zur Verminderung der Mortalität bei Patienten mit eingeschränkter myocardialer Funktion
US08/483,635 US5760069A (en) 1995-02-08 1995-06-07 Method of treatment for decreasing mortality resulting from congestive heart failure

Publications (1)

Publication Number Publication Date
ES2134588T3 true ES2134588T3 (es) 1999-10-01

Family

ID=26012210

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96902984T Expired - Lifetime ES2134588T3 (es) 1995-02-08 1996-02-07 Uso de compuestos de carbazol para la preparacion de un medicamento para el tratamiento de la insuficiencia cardiaca congestiva.

Country Status (27)

Country Link
US (6) US5760069A (es)
EP (1) EP0808162B1 (es)
JP (1) JP3546058B2 (es)
KR (1) KR100295940B1 (es)
CN (1) CN1093760C (es)
AT (1) ATE179891T1 (es)
AU (1) AU702106C (es)
BR (1) BR9607111A (es)
CA (1) CA2212548C (es)
CZ (1) CZ292002B6 (es)
DE (1) DE69602424T2 (es)
DK (1) DK0808162T3 (es)
ES (1) ES2134588T3 (es)
FI (1) FI973255A0 (es)
GR (1) GR3030966T3 (es)
HK (1) HK1014861A1 (es)
HU (1) HUP9900773A3 (es)
NO (1) NO314830B1 (es)
NZ (1) NZ301692A (es)
PL (1) PL321737A1 (es)
RO (1) RO121629B1 (es)
RU (1) RU2197242C2 (es)
SI (1) SI0808162T1 (es)
SK (1) SK106897A3 (es)
UA (1) UA55382C2 (es)
WO (1) WO1996024348A2 (es)
ZA (1) ZA96994B (es)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5760069A (en) * 1995-02-08 1998-06-02 Boehringer Mannheim Pharmaceuticals Corporation-Smithkline Beecham Corporation Limited Partnership #1 Method of treatment for decreasing mortality resulting from congestive heart failure
TR199900762T2 (xx) * 1996-10-09 1999-07-21 Boehringer Mannheim Pharmaceuticals Cor.Smithkline Beecham Stresle aktifle�tirilen protein kinazlar�n�n engellenme y�ntemi.
ZA989365B (en) * 1997-10-15 1999-04-15 Boehringer Mannheim Pharm Corp Preparation for treating alzheimer's disease
WO1999024017A1 (en) * 1997-11-12 1999-05-20 Boehringer Mannheim Pharmaceuticals Corporation - Smithkline Bechman Corporation Limited Partnership No.1 Novel oral dosage form for carvedilol
US20020054911A1 (en) * 2000-05-11 2002-05-09 Boehringer Mannheim Pharmaceutical Corporation-Sm Ithkline Beckman Corporation, Limited Partnershi Novel oral dosage form for carvedilol
US6664284B2 (en) 1998-07-23 2003-12-16 Roche Diagnostics Gmbh Stabilized carvedilol injection solution
DE19833119A1 (de) * 1998-07-23 2000-01-27 Roche Diagnostics Gmbh Spritzfertige Injektionslösungen enthaltend Carvedilol
PE20001302A1 (es) * 1998-11-27 2000-11-30 Hoffmann La Roche Preparaciones de una combinacion farmaceutica que contiene carvedilol e hidroclorotiazida
US6465463B1 (en) * 1999-09-08 2002-10-15 Nitromed, Inc. Methods of treating and preventing congestive heart failure with hydralazine compounds and isosorbide dinitrate or isosorbide mononitrate
US7235237B2 (en) * 1999-10-29 2007-06-26 Nitromed, Inc. Methods of treating vascular diseases characterized by nitric oxide insufficiency
WO2001035961A1 (en) * 1999-10-29 2001-05-25 Nitromed, Inc. Methods of treating vascular diseases characterized by nitric oxide insufficiency
US7708989B2 (en) * 1999-10-29 2010-05-04 Nitromed, Inc. Methods of treating vascular diseases characterized by nitric oxide insufficiency
US7537785B2 (en) * 1999-10-29 2009-05-26 Nitromed, Inc. Composition for treating vascular diseases characterized by nitric oxide insufficiency
US20010036959A1 (en) * 2000-04-03 2001-11-01 Gabel Rolf Dieter Carvedilol-hydrophilic solutions
MXPA02012795A (es) * 2000-06-28 2004-07-30 Teva Pharma Carvedilol.
EP1385509A4 (en) * 2001-04-02 2004-06-30 Smithkline Beecham Corp TREATMENT METHOD
WO2003028718A1 (en) * 2001-10-01 2003-04-10 Smithkline Beecham Corporation Novel formulations of carvedilol
EP1465620A4 (en) * 2001-10-02 2006-01-25 Smithkline Beecham Corp NEW COMPOSITION OF CARVEDILOL
US8101209B2 (en) 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
SE0103749D0 (sv) * 2001-11-08 2001-11-08 Sahltech Ab Treatment of congestive heart failure
PL371409A1 (en) * 2002-01-15 2005-06-13 Teva Pharmaceutical Industries Ltd. Crystalline solids of carvedilol and processes for their preparation
CN1649614A (zh) 2002-02-22 2005-08-03 新河药品股份有限公司 活性剂传递系统和保护及施用活性剂的方法
EP1499310A4 (en) * 2002-04-30 2005-12-07 Sb Pharmco Inc MONOCITRATE MONOHYDRATE OF CARVEDILOL
US6951880B2 (en) * 2002-05-16 2005-10-04 Genelabs Technologies, Inc. Aryl and heteroaryl compounds as antibacterial and antifungal agents
US20050261355A1 (en) * 2002-06-27 2005-11-24 Sb Pharmco Puerto Rico Inc., Carvedilol hydobromide
MXPA04012923A (es) * 2002-06-27 2005-03-31 Sb Pharmco Inc Sales de fosfato de carvedilol y/o solvatos de las mismas, composiciones correspondientes y/o metodos de tratamiento.
PT1362590E (pt) * 2002-07-25 2004-05-31 Boehringer Ingelheim Pharma Utilizacao de cilobradina ou dos seus sais farmaceuticamente aceitaveis para o tratamento ou prevencao de falha cardiaca
US6632832B1 (en) 2002-09-10 2003-10-14 Dabur Research Foundation Anti-cancer activity of carvedilol and its isomers
US20050032879A1 (en) * 2003-08-07 2005-02-10 Temple Okarter Formulations and use of a beta-blocker and an ACE-inhibitor for the treatment of cardiovascular diseases
US20050175695A1 (en) * 2003-11-25 2005-08-11 Catherine Castan Carvedilol free base, salts, anhydrous forms or solvates thereof, corresponding pharmaceutical compositions, controlled release formulations, and treatment or delivery methods
JP2007512350A (ja) * 2003-11-25 2007-05-17 エスビー・ファルムコ・プエルト・リコ・インコーポレイテッド カルベジロール組成物の治療および送達方法
JP2007512372A (ja) * 2003-11-25 2007-05-17 エスビー・ファルムコ・プエルト・リコ・インコーポレイテッド カルベジロール塩、対応する組成物、送達および／または治療方法
US20060014829A1 (en) * 2004-07-16 2006-01-19 Nitromed, Inc. Methods for reducing hospitalizations related to heart failure
US20070043099A1 (en) * 2005-06-09 2007-02-22 Igor Lifshitz Crystalline forms of carvedilol and processes for their preparation
US20080293724A1 (en) * 2006-02-17 2008-11-27 Nitromed, Inc. Methods Using Hydralazine Compounds and Isosorbide Dinitrate or Isosorbide Mononitrate
US8367112B2 (en) * 2006-02-28 2013-02-05 Alkermes Pharma Ireland Limited Nanoparticulate carverdilol formulations
US8703804B2 (en) * 2006-03-26 2014-04-22 Uti Limited Partnership Ryanodine receptor inhibitors and methods relating thereto
WO2007136626A1 (en) * 2006-05-16 2007-11-29 Nitromed, Inc. Solid dosage formulations of hydralazine compounds
US8022094B2 (en) * 2006-06-28 2011-09-20 Teva Pharmaceutical Industries Ltd. Carvedilol phosphate
WO2008105794A1 (en) * 2007-02-26 2008-09-04 Teva Pharmaceutical Industries Ltd. Process for the purification of carvedilol or its salts thereof
US20090076116A1 (en) * 2007-09-13 2009-03-19 Protia, Llc Deuterium-enriched carvediolo
EA022948B1 (ru) 2008-05-16 2016-03-31 Кортера, Инк. Лечение релаксином одышки, ассоциированной с острой сердечной недостаточностью
MX357614B (es) * 2010-04-12 2018-07-17 Supernus Pharmaceuticals Inc Métodos para producir sales de viloxazina y polimorfos novedosos de las mismas.
JP2014521713A (ja) 2011-08-12 2014-08-28 ベーリンガー インゲルハイム フェトメディカ ゲゼルシャフト ミット ベシュレンクテル ハフツング 味をマスキングした医薬組成物
CN110381929A (zh) * 2016-06-13 2019-10-25 阿森迪亚制药有限责任公司 卡维地洛分散系统的肠胃外缓释传递
US10772869B1 (en) 2019-07-24 2020-09-15 ECI Pharmaceuticals, LLC Pharmaceutical compositions including carvedilol and methods of using the same

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2815926A1 (de) 1978-04-13 1979-10-18 Boehringer Mannheim Gmbh Neue carbazolyl-(4)-oxy-propanolamin-derivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
DE3319027A1 (de) 1983-05-26 1984-11-29 Boehringer Mannheim Gmbh, 6800 Mannheim Verfahren zur herstellung von optisch aktiven carbazol-derivaten, neue r- und s-carbazol-derivate, sowie arzneimittel, die diese verbindungen enthalten
SE460945B (sv) * 1987-01-15 1989-12-11 Lejus Medical Ab En multipel-unit-dos komposition av furosemid
US5312828A (en) * 1989-06-14 1994-05-17 Finkelstein Joseph A Substituted imidazoles having angiotensin II receptor blocking activity
US5308862A (en) * 1993-03-05 1994-05-03 Boehringer Mannheim Pharmaceuticals Corporation - Smithkline Beecham Corp., Ltd. Partnership No. 1 Use of, and method of treatment using, carbazolyl-(4)-oxypropanolamine compounds for inhibition of smooth muscle cell proliferation
US5760069A (en) 1995-02-08 1998-06-02 Boehringer Mannheim Pharmaceuticals Corporation-Smithkline Beecham Corporation Limited Partnership #1 Method of treatment for decreasing mortality resulting from congestive heart failure

Also Published As

Publication number Publication date
UA55382C2 (uk) 2003-04-15
US5902821A (en) 1999-05-11
KR19980702085A (ko) 1998-07-15
DE69602424D1 (de) 1999-06-17
BR9607111A (pt) 1997-11-04
EP0808162A2 (en) 1997-11-26
US5760069A (en) 1998-06-02
KR100295940B1 (ko) 2001-08-07
HUP9900773A2 (hu) 1999-07-28
DE69602424T2 (de) 1999-10-07
CA2212548C (en) 1999-08-24
JP3546058B2 (ja) 2004-07-21
US20030105138A1 (en) 2003-06-05
EP0808162B1 (en) 1999-05-12
PL321737A1 (en) 1997-12-22
CN1185106A (zh) 1998-06-17
CZ292002B6 (cs) 2003-07-16
HK1014861A1 (en) 1999-10-08
USRE40707E1 (en) 2009-05-05
GR3030966T3 (en) 1999-11-30
DK0808162T3 (da) 1999-11-15
RO121629B1 (ro) 2008-01-30
SI0808162T1 (en) 1999-10-31
USRE40000E1 (en) 2008-01-08
HUP9900773A3 (en) 2000-04-28
NO314830B1 (no) 2003-06-02
MX9706042A (es) 1998-06-30
WO1996024348A3 (en) 1996-10-03
ZA96994B (en) 1997-10-27
NZ301692A (en) 2000-09-29
WO1996024348A2 (en) 1996-08-15
AU702106C (en) 2005-02-17
AU702106B2 (en) 1999-02-11
FI973255A (fi) 1997-08-07
US20010044455A1 (en) 2001-11-22
NO973667D0 (no) 1997-08-08
FI973255A0 (fi) 1997-08-07
CN1093760C (zh) 2002-11-06
CZ246397A3 (cs) 1998-11-11
NO973667L (no) 1997-08-08
CA2212548A1 (en) 1996-08-15
AU4718196A (en) 1996-08-27
RU2197242C2 (ru) 2003-01-27
ATE179891T1 (de) 1999-05-15
JPH10513463A (ja) 1998-12-22
SK106897A3 (en) 1999-03-12

Similar Documents

Publication Publication Date Title
ES2134588T3 (es) Uso de compuestos de carbazol para la preparacion de un medicamento para el tratamiento de la insuficiencia cardiaca congestiva.
RU97114836A (ru) Применение соединений карбазола для лечения застойной сердечной недостаточности
ES2112332T3 (es) Derivados de substitucion de oxigeno de productos de adicion de nucleofilo-oxido nitrico utilizados como promedicamentos donadores de oxido nitrico.
FI932891A0 (fi) Nya pyrazolderivat, foerfarande foer deras framstaellning och farmaceutiska preparat innehaollande desamma
CO5570109A1 (es) Compuestos de dihidropirimidina heterociclicos
CO5180649A1 (es) Antagonistas de los receptores de los glucocorticoides para el tratamiento de la diabetes para el tratamiento de la diabetes
ES2151192T3 (es) Compuestos de quinolina y quinazolina utiles en terapia.
EA199900756A1 (ru) Замещенные изохинолины в качестве нервно-мышечных блокаторов ультракраткосрочного действия
AU542481B2 (en) Substituted phenyl ethers
EA200000360A1 (ru) Оральные композиции левосимендана
ATE193012T1 (de) Prodrogen von stickstoff-senfen mit neuen lipophilischen schutzgruppen; und verfahren zu ihrer herstellung
PE62396A1 (es) Derivado de indol
AR009612A1 (es) Una composicion farmaceutica, un diaril-ciclometilenpirazol, un procedimiento para preparar un diaril-ciclometilenpirazol y comuestosintermedios
ES2181849T3 (es) Procedimiento para minimizar la perdida osea.
RU94030470A (ru) Производные 1-(арилалкиламиноалкил)имидазола, способ их получения, фармацевтическая композиция и способ лечения
RU95113434A (ru) Диметилбензофураны и диметилбензопираны, их применение в качестве 5-нт*003-антагонистов, способы их получения, фармацевтическая композиция
NO903532L (no) Fremgangsmaate for behandling av kardiell, saavel som vaskulaer hypertropi og hyperplasi.
ES2176609T3 (es) Derivados de hidratos de carbono.
ES2163715T3 (es) Compuestos y composiciones de naftilo.
KR880000461A (ko) 안드로스트-4-엔-3,17-디온 및 그의 제조방법
KR840003631A (ko) 아졸릴펜옥시- 테트라하이드로푸란-2-일리덴- 메탄의 제조방법
PT96557A (pt) Processo para a preparacao de derivados de ergolina e de composicoes farmaceuticas que os contem
ES2064919T3 (es) Derivados del acido bifenil 5,5'-bis-alcanoico, su fabricacion y utilizacion.
CA2150695A1 (en) Antioxidant neuroprotective use of, and method of treatment using, hydroxycarbazole compounds
ES2138612T3 (es) Triazoles sustituidos utiles como inhibidores de angiotensina ii.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 808162

Country of ref document: ES